Skip to main content
main-content

01.12.2012 | Research article | Ausgabe 1/2012 Open Access

BMC Health Services Research 1/2012

Evaluating the impact of a novel restricted reimbursement policy for quinolone antibiotics: A time series analysis

Zeitschrift:
BMC Health Services Research > Ausgabe 1/2012
Autoren:
Braden Manns, Kevin Laupland, Marcello Tonelli, Song Gao, Brenda Hemmelgarn
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1472-6963-12-290) contains supplementary material, which is available to authorized users.

Competing interests

All of the authors declare that they have no relevant competing interests.

Authors’ contributions

Dr M, L, T, and H made substantial contributions to study conception and design, drafting and critical revision. Dr M, H and G have all been involved with data analysis, and interpretation of data, and Dr G drafted the methods and results sections. All authors have approved the final version.

Abstract

Background

Publicly-funded drug plans often use prior authorization policies to limit drug prescribing. To guide physician prescribing of a class of antibiotics with broad antimicrobial activity (quinolone antibiotics) in accordance with new prescribing guidelines, Alberta’s provincial health ministry implemented a new mechanism for formulary restriction entitled the optional special authorization (OSA) program. We conducted an observational study to determine the impact of this new formulary restriction policy on antimicrobial prescription rates as well as any clinical consequences.

Methods

Quinolone antibiotic use, and adherence with quinolone prescribing guidelines, was assessed before and after implementation of the OSA program in patients with common outpatient infections using an administrative data cohort and a chart review cohort, respectively. At the same time this policy was implemented to limit quinolone prescribing, two new quinolone antibiotics were added to the formulary. Using administrative data, we analysed a total of 397,534 unique index visits with regard to overall antibiotic utilization, and through chart review, we analysed 1681 charts of patients with infections of interest to determine the indications for quinolone usage.

Results

Using segmented regression models adjusting for age, sex and physician enrollment in the OSA program, there was no statistically significant change in the monthly rate of all quinolone use (−3.5 (95% CI −5.5, 1.4) prescriptions per 1000 index visits) following implementation of the OSA program (p = 0.74). There was a significant level change in the rate of quinolone antibiotic use for urinary tract infection (−33.6 (95% CI: -23.8, -43.4) prescriptions and upper respiratory tract infection (−16.1 (95%CI: -11.6, -20.6) prescriptions per 1000 index visits. Among quinolone prescriptions identified on chart review, 42.5% and 58.5% were consistent with formulary guidelines before and after the implementation of the OSA program, respectively (p = 0.002). There was no change in hospitalization, mortality or use of physician services after implementation of the OSA program.

Conclusions

Despite the addition of two new quinolone antibiotics to the formulary, we found that there was no change in the use of quinolones after implementation of a new formulary restriction policy for outpatients with common outpatient infections.
Zusatzmaterial
Additional file 1: Blue cross.(DOC 268 KB)
12913_2011_2157_MOESM1_ESM.doc
Additional file 2: ICD-9 Diagnosis Codes for Outpatient Infections of Interest.(DOC 63 KB)
12913_2011_2157_MOESM2_ESM.doc
Authors’ original file for figure 1
12913_2011_2157_MOESM3_ESM.tiff
Authors’ original file for figure 2
12913_2011_2157_MOESM4_ESM.tiff
Authors’ original file for figure 3
12913_2011_2157_MOESM5_ESM.tiff
Authors’ original file for figure 4
12913_2011_2157_MOESM6_ESM.tiff
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

BMC Health Services Research 1/2012 Zur Ausgabe